Xbrane Biopharma AB Stock

Equities

XBRANE

SE0007789409

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 11:29:53 2024-04-26 am EDT 5-day change 1st Jan Change
0.2135 SEK -1.39% Intraday chart for Xbrane Biopharma AB -39.35% -97.86%
Sales 2024 * 344M 31.41M Sales 2025 * 680M 62.18M Capitalization 327M 29.85M
Net income 2024 * -101M -9.23M Net income 2025 * 104M 9.51M EV / Sales 2024 * 0.55 x
Net cash position 2024 * 138M 12.65M Net Debt 2025 * 116M 10.58M EV / Sales 2025 * 0.65 x
P/E ratio 2024 *
-1.58 x
P/E ratio 2025 *
-
Employees 93
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.11%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Xbrane Biopharma AB

1 day-1.39%
1 week-39.35%
Current month-29.19%
1 month-17.88%
3 months-86.57%
6 months-98.89%
Current year-97.86%
More quotes
1 week
0.19
Extreme 0.1862
0.27
1 month
0.19
Extreme 0.1862
0.43
Current year
0.19
Extreme 0.1862
10.84
1 year
0.19
Extreme 0.1862
94.20
3 years
0.19
Extreme 0.1862
180.40
5 years
0.19
Extreme 0.1862
180.40
10 years
0.19
Extreme 0.1862
180.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 14-12-31
Director of Finance/CFO 63 21-01-10
Chief Tech/Sci/R&D Officer 42 17-10-08
Members of the board TitleAgeSince
Director/Board Member 67 14-12-31
Director/Board Member 70 14-12-31
Director/Board Member 53 19-12-31
More insiders
Date Price Change Volume
24-04-26 0.2135 -1.39% 11,591,000
24-04-25 0.2165 +4.09% 37,415,150
24-04-24 0.208 -3.48% 49,579,610
24-04-23 0.2155 -8.30% 64,018,490
24-04-22 0.235 -33.24% 198,129,300

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT

More quotes
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.2135 SEK
Average target price
0.625 SEK
Spread / Average Target
+192.74%
Consensus
  1. Stock Market
  2. Equities
  3. XBRANE Stock